Travere Therapeutic News

Travere Therapeutics Analyst Ratings

BenzingaApr 24 14:36 ET

Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know

BenzingaApr 17 15:00 ET

Travere Therapeutics Analyst Ratings

BenzingaApr 17 13:22 ET

Travere Therapeutics Analyst Ratings

BenzingaMar 27 06:47 ET

Travere Therapeutics Analyst Ratings

BenzingaMar 13 09:43 ET

Travere Therapeutics Analyst Ratings

BenzingaFeb 16 08:56 ET

Wedbush Lifts Travere Therapeutics' Price Target to $13 From $12, Keeps Outperform Rating

MT NewswiresJan 29 07:29 ET

Travere Therapeutics Analyst Ratings

BenzingaJan 18 14:13 ET

Travere Therapeutics Analyst Ratings

BenzingaDec 18, 2023 10:53 ET

HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $20

BenzingaDec 15, 2023 13:40 ET

Travere Therapeutics Analyst Ratings

BenzingaDec 15, 2023 13:39 ET

Stifel Nicolaus Sticks to Its Hold Rating for Travere Therapeutics (TVTX)

TipRanksDec 5, 2023 07:28 ET

Citigroup Upgrades Travere Therapeutics to Buy, Raises Price Target to $10

BenzingaDec 5, 2023 07:22 ET

HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $18 Price Target

BenzingaDec 5, 2023 06:28 ET

Travere Therapeutics Analyst Ratings

BenzingaDec 5, 2023 06:26 ET

JPMorgan Adjusts Travere Therapeutics Price Target to $19 From $23, Maintains Overweight Rating

MT NewswiresNov 24, 2023 08:42 ET

Citigroup Initiates Coverage On Travere Therapeutics With Neutral Rating, Announces Price Target of $7

BenzingaNov 20, 2023 05:55 ET

Travere Therapeutics Analyst Ratings

BenzingaNov 20, 2023 05:54 ET

Travere Therapeutics Analyst Ratings

BenzingaOct 25, 2023 15:31 ET

Canaccord Genuity Cuts Travere Therapeutics Price Target to $15 From $35, Maintains Buy Rating

MT NewswiresOct 3, 2023 07:49 ET